• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CT检查时胃癌最大肿瘤直径缩小率作为新辅助治疗后组织病理学退缩的影像学预测指标:一项多中心GIRCG研究

Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study.

作者信息

Mazzei Maria Antonietta, Bagnacci Giulio, Gentili Francesco, Nigri Andrea, Pelini Veronica, Vindigni Carla, Mazzei Francesco Giuseppe, Baiocchi Gian Luca, Pittiani Frida, Morgagni Paolo, Petrella Enrico, Mura Gianni, Verdelli Beatrice, Bencivenga Maria, Giacopuzzi Simone, Marrelli Daniele, Roviello Franco, Volterrani Luca

机构信息

Department of Medical, Surgical and Neuro Sciences, Unit of Diagnostic Imaging, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy.

Faculty of Statistics, Sapienza University of Rome, Roma, Italy.

出版信息

Gastroenterol Res Pract. 2018 Mar 15;2018:1794524. doi: 10.1155/2018/1794524. eCollection 2018.

DOI:10.1155/2018/1794524
PMID:29736166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5875045/
Abstract

AIM

To investigate the role of maximum tumour diameter (D-max) reduction rate at CT examination in predicting histopathological tumour regression grade (TRG according to the Becker grade), after neoadjuvant chemotherapy (NAC), in patients with resectable advanced gastric cancer (AGC).

MATERIALS AND METHODS

Eighty-six patients (53 M, mean age 62.1 years) with resectable AGC (≥T3 or N+), treated with NAC and radical surgery, were enrolled from 5 centres of the Italian Research Group for Gastric Cancer (GIRCG). Staging and restaging CT and histological results were retrospectively reviewed. CT examinations were contrast enhanced, and the stomach was previously distended. The D-max was measured using 2D software and compared with Becker TRG. Statistical data were obtained using "R" software.

RESULTS

The interobserver agreement was good/very good. Becker TRG was predicted by CT with a sensitivity and specificity, respectively, of 97.3% and 90.9% for Becker 1 (D-max reduction rate > 65.1%), 76.4% and 80% for Becker 3 (D-max reduction rate < 29.9%), and 70.8% and 83.9% for Becker 2. Correlation between radiological and histological D-max measurements was strongly confirmed by the correlation index (c.i.= 0.829).

CONCLUSIONS

D-max reduction rate in AGC patients may be helpful as a simple and reproducible radiological index in predicting TRG after NAC.

摘要

目的

探讨在可切除的进展期胃癌(AGC)患者中,新辅助化疗(NAC)后CT检查时肿瘤最大直径(D-max)缩小率在预测组织病理学肿瘤退缩分级(根据Becker分级的TRG)中的作用。

材料与方法

从意大利胃癌研究组(GIRCG)的5个中心纳入86例(53例男性,平均年龄62.1岁)可切除的AGC(≥T3或N+)患者,这些患者接受了NAC和根治性手术。对分期和再分期CT及组织学结果进行回顾性分析。CT检查采用增强扫描,检查前胃已充盈。使用二维软件测量D-max,并与Becker TRG进行比较。使用“R”软件获取统计数据。

结果

观察者间一致性良好/非常好。CT对Becker TRG的预测,Becker 1级(D-max缩小率>65.1%)的敏感性和特异性分别为97.3%和90.9%,Becker 3级(D-max缩小率<29.9%)为76.4%和80%,Becker 2级为70.8%和83.9%。相关指数(c.i.=0.829)有力地证实了放射学和组织学D-max测量值之间的相关性。

结论

AGC患者的D-max缩小率作为一种简单且可重复的放射学指标,可能有助于预测NAC后的TRG。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/9647ea492418/GRP2018-1794524.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/b1e1e800750a/GRP2018-1794524.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/d1cc521c257e/GRP2018-1794524.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/5a21f2e445c7/GRP2018-1794524.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/056ab899291f/GRP2018-1794524.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/826d9ccf334c/GRP2018-1794524.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/bacbfabe65c3/GRP2018-1794524.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/52df3675db39/GRP2018-1794524.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/c46631c4b22b/GRP2018-1794524.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/9b4f8eb93c7b/GRP2018-1794524.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/df818b204e5f/GRP2018-1794524.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/9647ea492418/GRP2018-1794524.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/b1e1e800750a/GRP2018-1794524.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/d1cc521c257e/GRP2018-1794524.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/5a21f2e445c7/GRP2018-1794524.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/056ab899291f/GRP2018-1794524.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/826d9ccf334c/GRP2018-1794524.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/bacbfabe65c3/GRP2018-1794524.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/52df3675db39/GRP2018-1794524.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/c46631c4b22b/GRP2018-1794524.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/9b4f8eb93c7b/GRP2018-1794524.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/df818b204e5f/GRP2018-1794524.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb0/5875045/9647ea492418/GRP2018-1794524.012.jpg

相似文献

1
Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study.CT检查时胃癌最大肿瘤直径缩小率作为新辅助治疗后组织病理学退缩的影像学预测指标:一项多中心GIRCG研究
Gastroenterol Res Pract. 2018 Mar 15;2018:1794524. doi: 10.1155/2018/1794524. eCollection 2018.
2
Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer).Delta放射组学与局部晚期胃癌新辅助治疗反应——意大利胃癌研究组(GIRCG)的多中心研究
Quant Imaging Med Surg. 2021 Jun;11(6):2376-2387. doi: 10.21037/qims-20-683.
3
Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer.CT容积测量法对原发性胃病变在预测晚期胃癌新辅助化疗病理反应中的应用价值。
Abdom Imaging. 2009 Jul;34(4):430-40. doi: 10.1007/s00261-008-9420-8.
4
Interobserver agreement of a gastric adenocarcinoma tumor regression grading system that incorporates assessment of lymph nodes.包含淋巴结评估的胃腺癌肿瘤消退分级系统的观察者间一致性。
Hum Pathol. 2021 Oct;116:94-101. doi: 10.1016/j.humpath.2021.07.003. Epub 2021 Jul 17.
5
Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.接受诱导化疗和新辅助立体定向体部放疗的临界可切除和局部晚期胰腺癌病理肿瘤反应分级的预测因素及生存情况
Acta Oncol. 2017 Mar;56(3):391-397. doi: 10.1080/0284186X.2016.1256497. Epub 2016 Nov 25.
6
CT-Based Radiomics Showing Generalization to Predict Tumor Regression Grade for Advanced Gastric Cancer Treated With Neoadjuvant Chemotherapy.基于CT的影像组学在预测接受新辅助化疗的晚期胃癌肿瘤退缩分级中的泛化表现
Front Oncol. 2022 Feb 25;12:758863. doi: 10.3389/fonc.2022.758863. eCollection 2022.
7
Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy.新辅助化疗后局部晚期胃腺癌肿瘤退缩分级系统的比较
World J Gastrointest Oncol. 2021 Dec 15;13(12):2161-2179. doi: 10.4251/wjgo.v13.i12.2161.
8
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.优化新辅助治疗食管腺癌的病理评估。
World J Gastroenterol. 2013 Dec 28;19(48):9282-93. doi: 10.3748/wjg.v19.i48.9282.
9
Multidetector CT for Restaging Locally Advanced Esophageal Squamous Cell Carcinoma and Assessing Therapeutic Response to Neoadjuvant Chemotherapy.多排螺旋CT用于局部进展期食管鳞状细胞癌的再分期及评估新辅助化疗的治疗反应
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2017 Feb 20;39(1):133-139. doi: 10.3881/j.issn.1000-503X.2017.01.022.
10
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.可切除胃食管腺癌患者接受铂类新辅助化疗后的肿瘤退缩分级(TRG)分析。
Histopathology. 2009 Oct;55(4):399-406. doi: 10.1111/j.1365-2559.2009.03404.x.

引用本文的文献

1
Discordance in tumour response assessment for gastric cancer after neoadjuvant chemotherapy using different methods.使用不同方法对胃癌新辅助化疗后的肿瘤反应评估存在不一致性。
Abdom Radiol (NY). 2025 Sep 9. doi: 10.1007/s00261-025-05187-1.
2
International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape : Bertinoro Workshop, November 2022.国际转移性胃癌管理共识:在雾霭重重的领域中步步前行:贝蒂诺罗研讨会,2022 年 11 月。
Gastric Cancer. 2024 Jul;27(4):649-671. doi: 10.1007/s10120-024-01479-5. Epub 2024 Apr 18.
3
The role of computed tomography features in assessing response to neoadjuvant chemotherapy in locally advanced gastric cancer.

本文引用的文献

1
Incidence and Prognostic Value of Metastases to "Posterior" and Para-aortic Lymph Nodes in Resectable Gastric Cancer.可切除胃癌中“后”部和腹主动脉旁淋巴结转移的发生率和预后价值。
Ann Surg Oncol. 2017 Aug;24(8):2273-2280. doi: 10.1245/s10434-017-5857-8. Epub 2017 Apr 12.
2
Effect of neoadjuvant chemotherapy on HER-2 expression in surgically treated gastric and oesophagogastric junction carcinoma: a multicentre Italian study.新辅助化疗对手术治疗的胃癌和食管胃交界癌中HER-2表达的影响:一项意大利多中心研究
Updates Surg. 2017 Mar;69(1):35-43. doi: 10.1007/s13304-017-0423-2. Epub 2017 Mar 8.
3
The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015.
计算机断层扫描特征在评估局部晚期胃癌新辅助化疗反应中的作用。
BMC Cancer. 2023 Nov 27;23(1):1157. doi: 10.1186/s12885-023-11619-2.
4
Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy.胃癌新辅助化疗疗效评估的影像学进展。
Abdom Radiol (NY). 2023 Dec;48(12):3661-3676. doi: 10.1007/s00261-023-04046-1. Epub 2023 Oct 3.
5
Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer.术前生物学指标与可切除胃癌新辅助/围手术期化疗依从性的相关性。
Nutrients. 2023 Aug 17;15(16):3604. doi: 10.3390/nu15163604.
6
Response Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Cancer.可切除胃癌新辅助化疗后的疗效评估
Cancers (Basel). 2023 Apr 15;15(8):2318. doi: 10.3390/cancers15082318.
7
Some Concerns from a Radiological Point of View. Comment on Huang et al. Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone. 2022, , 555.放射学视角的一些担忧。对黄等人的评论。转移性胃癌转化手术与先行手术加姑息化疗或单纯先行手术的疗效比较。2022年,,555。
J Pers Med. 2022 Jun 29;12(7):1061. doi: 10.3390/jpm12071061.
8
Down-staging depth score could be a survival predictor for locally advanced gastric cancer patients after preoperative chemoradiotherapy.降期深度评分可能是局部进展期胃癌患者术前放化疗后的生存预测指标。
Chin J Cancer Res. 2021 Aug 31;33(4):447-456. doi: 10.21147/j.issn.1000-9604.2021.04.02.
9
Structured and shared CT radiological report of gastric cancer: a consensus proposal by the Italian Research Group for Gastric Cancer (GIRCG) and the Italian Society of Medical and Interventional Radiology (SIRM).胃癌 CT 影像学报告结构化和共享:意大利胃癌研究组(GIRCG)和意大利医学与介入放射学会(SIRM)的共识建议。
Eur Radiol. 2022 Feb;32(2):938-949. doi: 10.1007/s00330-021-08205-0. Epub 2021 Aug 12.
10
The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study.新辅助化疗后可切除胃癌的再分期 CT 的价值:一项基于人群的研究。
World J Surg Oncol. 2021 Jul 13;19(1):212. doi: 10.1186/s12957-021-02313-3.
意大利胃癌研究小组(GIRCG)胃癌分期与治疗指南:2015年版
Gastric Cancer. 2017 Jan;20(1):20-30. doi: 10.1007/s10120-016-0615-3. Epub 2016 Jun 2.
4
Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer.一项比较新辅助化疗联合 S-1 和顺铂(SC)两周期与四周期,以及紫杉醇联合顺铂(PC)方案,序贯 D2 胃切除术治疗可切除局部进展期胃癌的随机、两因素、二期临床试验的生存结果。
Eur J Cancer. 2016 Jul;62:103-11. doi: 10.1016/j.ejca.2016.04.012. Epub 2016 May 28.
5
Tumor regression grade in gastric cancer: Predictors and impact on outcome.胃癌中的肿瘤消退分级:预测因素及其对预后的影响。
J Surg Oncol. 2016 Sep;114(4):434-9. doi: 10.1002/jso.24307. Epub 2016 May 20.
6
New Imaging in Gastrointestinal Tract.胃肠道的新型成像技术
Gastroenterol Res Pract. 2016;2016:5785871. doi: 10.1155/2016/5785871. Epub 2016 Feb 4.
7
Histological evaluation for chemotherapeutic responses of metastatic lymph nodes in gastric cancer.胃癌转移性淋巴结化疗反应的组织学评估
World J Gastroenterol. 2015 Dec 28;21(48):13500-6. doi: 10.3748/wjg.v21.i48.13500.
8
Multimodal treatment of gastric cancer in the west: Where are we going?西方胃癌的多模式治疗:我们将何去何从?
World J Gastroenterol. 2015 Jul 14;21(26):7954-69. doi: 10.3748/wjg.v21.i26.7954.
9
Errors in multidetector row computed tomography.多排螺旋 CT 中的误差。
Radiol Med. 2015 Sep;120(9):785-94. doi: 10.1007/s11547-015-0558-5. Epub 2015 Jun 25.
10
CT perfusion: technical developments and current and future applications.CT灌注成像:技术发展及当前与未来的应用
Biomed Res Int. 2015;2015:397521. doi: 10.1155/2015/397521. Epub 2015 Jan 28.